Capital Asset Advisory Services LLC Has $329,000 Stake in Johnson & Johnson (NYSE:JNJ)

Capital Asset Advisory Services LLC boosted its position in Johnson & Johnson (NYSE:JNJ) by 6.1% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,360 shares of the company’s stock after buying an additional 135 shares during the quarter. Capital Asset Advisory Services LLC’s holdings in Johnson & Johnson were worth $329,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the company. Liberty Capital Management Inc. increased its stake in Johnson & Johnson by 13.2% in the 2nd quarter. Liberty Capital Management Inc. now owns 7,948 shares of the company’s stock valued at $1,107,000 after buying an additional 925 shares during the period. WoodTrust Financial Corp increased its stake in Johnson & Johnson by 3.5% in the 2nd quarter. WoodTrust Financial Corp now owns 44,487 shares of the company’s stock valued at $6,196,000 after buying an additional 1,520 shares during the period. Raymond James Trust N.A. increased its stake in shares of Johnson & Johnson by 3.6% during the 2nd quarter. Raymond James Trust N.A. now owns 161,872 shares of the company’s stock worth $22,546,000 after purchasing an additional 5,561 shares during the last quarter. Legacy Advisors LLC increased its stake in shares of Johnson & Johnson by 0.5% during the 2nd quarter. Legacy Advisors LLC now owns 23,639 shares of the company’s stock worth $3,292,000 after purchasing an additional 119 shares during the last quarter. Finally, Centre Asset Management LLC increased its stake in shares of Johnson & Johnson by 7.5% during the 2nd quarter. Centre Asset Management LLC now owns 54,200 shares of the company’s stock worth $7,549,000 after purchasing an additional 3,760 shares during the last quarter. Institutional investors and hedge funds own 67.35% of the company’s stock.

Shares of NYSE:JNJ opened at $130.54 on Friday. The company has a 50 day moving average of $134.10 and a 200-day moving average of $136.70. Johnson & Johnson has a one year low of $121.00 and a one year high of $148.99. The stock has a market cap of $352.12 billion, a price-to-earnings ratio of 15.96, a P/E/G ratio of 2.26 and a beta of 0.69. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.33 and a quick ratio of 1.04.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, July 16th. The company reported $2.58 earnings per share for the quarter, topping the consensus estimate of $2.42 by $0.16. Johnson & Johnson had a net margin of 20.08% and a return on equity of 38.63%. The business had revenue of $20.56 billion for the quarter, compared to analyst estimates of $20.39 billion. During the same quarter last year, the firm earned $2.10 EPS. Johnson & Johnson’s quarterly revenue was down 1.3% compared to the same quarter last year. Equities research analysts anticipate that Johnson & Johnson will post 8.6 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Tuesday, August 27th will be paid a $0.95 dividend. This represents a $3.80 dividend on an annualized basis and a yield of 2.91%. The ex-dividend date is Monday, August 26th. Johnson & Johnson’s payout ratio is currently 46.45%.

Several research analysts have recently commented on JNJ shares. Barclays initiated coverage on shares of Johnson & Johnson in a research note on Friday, June 21st. They set a “hold” rating and a $140.00 price target on the stock. Credit Suisse Group set a $156.00 target price on shares of Johnson & Johnson and gave the company a “buy” rating in a research note on Thursday, July 18th. Zacks Investment Research lowered shares of Johnson & Johnson from a “buy” rating to a “hold” rating and set a $139.00 target price on the stock. in a research note on Thursday, July 18th. Raymond James reduced their price target on shares of Johnson & Johnson from $147.00 to $146.00 and set an “outperform” rating for the company in a report on Wednesday, July 17th. Finally, Bank of America reaffirmed a “hold” rating and set a $150.00 price objective on shares of Johnson & Johnson in a report on Tuesday, July 16th. Five analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Johnson & Johnson has an average rating of “Buy” and a consensus price target of $148.56.

In related news, Director Marillyn A. Hewson purchased 3,000 shares of the business’s stock in a transaction on Tuesday, June 11th. The shares were purchased at an average price of $139.68 per share, with a total value of $419,040.00. Following the completion of the purchase, the director now owns 3,000 shares in the company, valued at approximately $419,040. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 0.23% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Featured Article: Municipal Bonds

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.